The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Janux Therapeutics Inc (NASDAQ: JANX) closed at $46.25 down -0.79% from its previous closing price of $46.62. In other words, the price has decreased by -$0.79 from its previous closing price. On the day, 0.54 million shares were traded. JANX stock price reached its highest trading level at $48.27 during the session, while it also had its lowest trading level at $45.55.
Ratios:
For a deeper understanding of Janux Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 57.34 and its Current Ratio is at 57.34. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on September 06, 2024, initiated with a Buy rating and assigned the stock a target price of $70.
On May 30, 2024, Scotiabank started tracking the stock assigning a Sector Perform rating and target price of $47.
On March 21, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $62.BTIG Research initiated its Buy rating on March 21, 2024, with a $62 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 27 ’24 when Meyer Andrew Hollman sold 50,000 shares for $45.96 per share. The transaction valued at 2,297,755 led to the insider holds 67,592 shares of the business.
DiRaimondo Thomas sold 5,000 shares of JANX for $231,716 on Sep 27 ’24. The Chief Scientific Officer now owns 97,938 shares after completing the transaction at $46.34 per share. On Sep 27 ’24, another insider, Campbell David Alan, who serves as the President and CEO of the company, sold 25,000 shares for $46.31 each. As a result, the insider received 1,157,641 and left with 307,054 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2412608000 and an Enterprise Value of 1790029440. For the stock, the TTM Price-to-Sale (P/S) ratio is 159.44 while its Price-to-Book (P/B) ratio in mrq is 3.67. Its current Enterprise Value per Revenue stands at 118.333 whereas that against EBITDA is -28.029.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $65.60, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is 5.58%, while the 200-Day Moving Average is calculated to be 29.85%.
Shares Statistics:
For the past three months, JANX has traded an average of 583.08K shares per day and 646330 over the past ten days. A total of 46.25M shares are outstanding, with a floating share count of 38.62M. Insiders hold about 25.96% of the company’s shares, while institutions hold 80.26% stake in the company. Shares short for JANX as of 1726185600 were 3305621 with a Short Ratio of 5.67, compared to 1723680000 on 3251084. Therefore, it implies a Short% of Shares Outstanding of 3305621 and a Short% of Float of 12.529999.
